Bronchoscope - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The bronchoscope market size is projected to expand from USD 4.40 billion in 2025 and USD 4.71 billion in 2026 to USD 6.65 billion by 2031, registering a CAGR of 7.15% between 2026 to 2031. This report is Segmented by Product Type (Rigid, Flexible, and Accessories), Usage (Single Use Bronchoscope and Reusable Bronchoscope), Application (Oncology, Pneumonia & Infection Diagnosis, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

Global Bronchoscope Market Trends and Insights

Growing Burden of Respiratory Diseases & Lung Cancer

GLOBOCAN 2022 logged 2.48 million new lung-cancer cases worldwide and projects 4.62 million by 2050, with Asia responsible for 63% of the load. The 2024 U.S. screening-age reduction to 50 years added 6.4 million eligible adults, stretching interventional capacity and reinforcing robotic bronchoscopy adoption. Chronic obstructive pulmonary disease affects more than 390 million people, underpinning baseline diagnostic demand. Rising case volumes draw bronchoscopy closer to primary care, rewarding portable, single-use devices that avoid capital outlays. China’s 28% jump in lung-cancer diagnoses from 2019-2024 highlights a geographic imbalance that tele-mentored bronchoscopy may help address.

Rapid Adoption of AI-Guided Navigation Bronchoscopy

Johnson & Johnson’s MONARCH QUEST, cleared in March 2025, automates path planning and trims catheter repositioning by 35-40%. Intuitive Surgical’s Ion upgrade gained clearance in October 2025 and now tops 900 global installs, using shape-sensing fiber optics to lift diagnostic yield to roughly 82%. Meta-analysis data place robotic yield 8-11 percentage points above traditional electromagnetic navigation. Noah Medical’s single-use Galaxy system extends these gains to ambulatory settings by embedding real-time tomosynthesis imaging. The shorter 40-60-case proficiency curve alleviates workforce bottlenecks, a critical lever where trained specialists are scarce.

High Overhead Cost of Bronchoscopy Procedure

A 2024 CHEST analysis placed U.S. outpatient bronchoscopy at USD 2,800-3,500 per case, dropping to USD 1,800-2,200 in ASCs yet still beyond reach in markets where annual per-capita health spend is under USD 500. India’s 48% out-of-pocket share limits access to urban insured populations. CMS trimmed payment by 2.8% in the 2025 fee schedule, intensifying throughput pressure. Robotic platforms partly offset cost by elevating first-pass success, but anesthesia and monitoring remain fixed expenses.

Other drivers and restraints analyzed in the detailed report include:

• Reimbursement Expansion for Single-Use Bronchoscopes
• Shift Toward Office-Based/ASC Bronchoscopy
• Shortage of Trained Interventional Pulmonologists

Segment Analysis

Flexible bronchoscopes owned 62.56% of bronchoscope market share in 2025 and are projected to expand at 10.25% CAGR to 2031, buoyed by robotic platforms that reach peripheral nodules previously inaccessible to manual scopes. Rigid scopes stay confined to central airway work in operating rooms and therefore grow slowly. Accessory disposables, ranging from biopsy forceps to cryoprobes, create a recurring revenue layer that scales with every additional procedure.

Robotic navigation raises diagnostic accuracy from about 70% with standard flexible scopes to 80-84%, pivoting clinical preference toward the new generation of intelligent instruments. Disposable accessories align with infection-control policies and avoid reprocessing downtime. Medtronic’s cryobiopsy probes, introduced in 2024, are expanding tissue-sampling indications, further lifting procedure complexity and volume.

Reusable devices represented 65.53% of the bronchoscope market size in 2025 because hospitals still rely on installed capital fleets. Yet single-use scopes are accelerating at 15.85% CAGR, thanks to pass-through reimbursement that offsets their higher variable cost. Ambu and Boston Scientific command early traction in ASCs that lack centralized sterilization.

A reusable scope amortized across 400-500 uses averages USD 150-250 per case; contamination incidents and labor costs tilt the equation as FDA alerts increase board scrutiny. Single-use options deliver 1080p imaging in models such as Ambu’s aScope 5, removing historic performance gaps. When pass-through payments sunset in 2026, device makers must prove long-term economic value to sustain adoption.

Complete Report Scope:

• By Product Type
  • Rigid
  • Flexible
  • Accessories
• By Usage
  • Single-use Bronchoscope
  • Reusable Bronchoscope
• By Application
  • Oncology (biopsy & staging)
  • Pneumonia & Infection Diagnosis
  • Foreign-body Removal
  • ICU Airway Management
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics & Office-based Labs
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 42.13% of bronchoscope market share in 2025 on the back of 180-220 procedures per 100,000 population and early robotic uptake. The 2024 screening-age drop expanded the eligible pool by 6.4 million, yet trained-specialist shortages lengthened waitlists in many states. HCPCS C1601 accelerates single-use adoption across 6,308 ASCs, while Canada’s capped reimbursement and 4-8-week waits are spawning private clinics. Mexican demand divides between urban private hospitals and under-equipped public centers.

Asia-Pacific outpaces all regions at 9.51% CAGR through 2031. China’s state screening pushes, India’s respiratory-care expansion, and South Korea’s 2024 coverage of robotic bronchoscopy drive volume. Japan’s 28% senior population sustains COPD-related demand; however, 2024 reimbursement cuts encourage disposable-scope adoption to save labor costs. Australia’s 2024 clearance of Ambu’s aScope 5 extends services to remote clinics lacking sterilization.

Europe holds roughly one-quarter of global revenue and sees heterogeneous policy environments. Germany’s DRG incentives promote robotics for efficiency; Charité reported a 22% volume spike after installing Ion in 2024. NHS England pilots single-use scopes in community centers to cut 12-week waits. France added outpatient reimbursement in 2024 after a contamination scare. Fiscal limits in Italy and Spain postpone capital upgrades. Middle East programs in the UAE and Saudi Arabia broaden screening, whereas Latin American growth hinges on Brazilian and Argentine private sectors amid public-sector shortfalls.

List of Companies Covered in this Report:

• Ambu
• Boston Scientific
• Broncus Medical
• Conmed
• Cook Group
• FUJIFILM
• Karl Storz
• Lymol Medical
• Medtronic
• Micro-tech
• Neuwe Med
• Novatech
• Olympus
• Pentax Medical
• Richard Wolf
• Teleflex
• Verathon

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support